The Plaintiffs’ Leadership, which includes Herman, Herman & Katz, LLC partner, Leonard A. Davis (Co-Plaintiffs’ Liaison Counsel), and Defendants, Bayer Healthcare and Janssen Pharmaceuticals, Inc., a subsidiary of Johnson & Johnson, entered into an Agreement/Memorandum of Understanding (“MOU”) on March 25, 2019 to create a program to end the Xarelto® litigation across the country and to resolve claims involving injuries alleged to have resulted from the use of XARELTO®. Full details regarding the Settlement Program will be available in the next few weeks, which will include information concerning registration of claims and eligibility requirements. The aggregate settlement amount is $775,000,000.00. The Settlement Program will resolve all claims between Plaintiffs and Defendants, and a Claims Administrator and Special Master will be appointed to manage the claims process. Questions regarding the settlement or Xarelto claims should be directed to Regina Valenti at Herman, Herman & Katz, LLC.
Free Case Evaluation
More About HHK
At HHK, we understand how devastating hurricanes and natural disasters […]
In 2021, Louisiana’s state legislature created a lookback window until […]
Lawsuits involving Medicare fraud are making headlines regularly. Investigators frequently expose and charge people with healthcare fraud, yet billions are still lost each year.
More than 42 million Americans have experienced sexual abuse; many […]
Offshore oil workers hold one of the most dangerous job […]
In 2021, the Louisiana legislature passed a bill allowing child […]